CancerCareE is an independent cancer information resource. We don't make medical decisions — we make medical information easier to understand.

Independent cancer information. We don't make medical decisions.

Please don't send medical records through our contact channels. We don't receive or review them.

Don't send medical records — we don't receive them.

Medical Disclaimer: This page is an educational registry framework and access-intelligence resource. It is not medical advice, a treatment recommendation, or a guarantee of trial enrollment. CancerCareE is not a hospital, clinical-trial sponsor, or medical provider. Final eligibility is determined solely by the study investigators and your treating oncologist. Always verify current status directly with the official registry and study center.
Editorial & Review Information
Published2026-10-24
Last Reviewed2026-10-24
Reviewed ByCancerCareE Editorial Team
Content TypeRegistry Framework / Access Intelligence
Evidence LevelPublic Registry Methodology + Published Sources
Living Registry Framework · October 2026

CAR-T Clinical Trial Registry in China

This page provides a structured framework for discovering and investigating CAR-T clinical trials registered in China. It explains what public registry data can and cannot tell you, how to distinguish “registered” from “recruiting” from “accessible to international patients,” and what steps to take before making any travel or financial commitment. The registry table below is a template requiring population from verified sources; no trial records have been fabricated.

2 registries Primary public sources: ClinicalTrials.gov and ChiCTR
Not verified Total active CAR-T trial count in China (requires methodology-based calculation)
Case by case International-patient access — never inferred from registration status

Quick Answer

A trial appearing on ClinicalTrials.gov or ChiCTR means it is registered, not that it is currently recruiting, and certainly not that it is open to international patients. To investigate a trial, start with the official registry entry, verify the recruitment status and last-update date, then contact the study center directly to confirm current enrollment and cross-border eligibility. CancerCareE does not rank trials or guarantee access.

Memory Anchor

“Registered does not mean recruiting. Recruiting does not mean accessible. Accessible does not mean suitable for you.”

Who This Page Is Not For

This page is not for patients seeking a guaranteed trial spot, a hospital recommendation, or a clinical eligibility assessment. It is not a substitute for the official protocol or informed-consent document. If you have not discussed clinical-trial participation with your local oncologist, that conversation should come first.

How This Registry Is Compiled

This registry framework is designed to be populated from the following publicly accessible sources. No trial record is listed unless it can be traced to an official registry entry with a verifiable identifier.

Source Registries

  • ClinicalTrials.gov — The largest public registry, operated by the U.S. National Library of Medicine. Search for condition terms (e.g., “B-cell lymphoma,” “multiple myeloma”) combined with location “China” and intervention “CAR-T.” clinicaltrials.gov
  • Chinese Clinical Trial Registry (ChiCTR) — A WHO primary registry operated by the Chinese Ministry of Health. ChiCTR records may include investigator-initiated studies not listed on ClinicalTrials.gov. chictr.org.cn
  • Center for Drug Evaluation (CDE), NMPA — For regulatory context on investigational new drug applications, where publicly accessible. This is not a trial-listing registry but can inform verification.

Scope and Definitions

  • Geography: “China” in this framework refers to mainland China. Hong Kong, Macau, and Taiwan are not included unless a specific trial record explicitly lists a site in those jurisdictions.
  • Study types included: Interventional CAR-T trials with a registered identifier. Observational studies are included only when explicitly labeled as such and kept in a separate category.
  • Cell therapies excluded from CAR-T counts: CAR-NK, TCR-T, TIL therapy, unmodified NK-cell therapy, and other cellular therapies are not counted as CAR-T studies. If referenced for context, they are placed in a separate category.
  • Recruitment status normalization: Statuses are reported exactly as displayed in the registry record at the time of check. “Recruiting,” “Not yet recruiting,” “Active, not recruiting,” “Completed,” “Terminated,” “Suspended,” “Withdrawn,” and “Unknown” are preserved verbatim.
  • Verification standard: A field is marked “Verified by CancerCareE” only if a member of the editorial team has opened the official registry entry and confirmed the field value on a recorded date. All other fields are marked “From registry — not independently verified.”
Critical limitation: Registry records are often updated infrequently. A status of “Recruiting” may be months old. Public contact information may be incomplete or may route to a coordinating office rather than the clinical team. No registry entry alone is sufficient to establish current availability or eligibility.

Registry Template: Required Data Fields

The table below defines the structure for each trial record. It is intentionally not populated with fabricated data. To populate it, each field must be extracted from the linked official registry entry and, where applicable, confirmed with the study center. A separate detail section can be created for each trial if the main table becomes unreadable.

Field Definition and Verification Rule Example Format
Study titleOfficial title as listed in the registry“A Phase 1/2 Study of CD19/CD22 CAR-T in Relapsed B-ALL”
Registry identifierNCT number (ClinicalTrials.gov) or ChiCTR numberNCT0XXXXXXX / ChiCTRXXXXXXXXXX
Direct registry linkURL to the official recordhttps://clinicaltrials.gov/study/NCT...
Primary cancer/diseaseCondition as listed in the registryDiffuse Large B-Cell Lymphoma (DLBCL)
CAR-T targetOnly when explicitly stated in the record (e.g., CD19, BCMA, GPC3, CLDN18.2)CD19
Cell product / approachTerminology used in the original recordAutologous anti-CD19 CAR-T
PhasePhase as listed (Early Phase 1, Phase 1, Phase 1/2, Phase 2, Phase 3)Phase 1/2
Recruitment statusVerbatim from registry at last check dateRecruiting
Study locationCity/province as listedBeijing, China
Named hospital/institutionOnly if explicitly identified in the registryChinese PLA General Hospital
Principal investigatorOnly if officially listed and verifiableNot listed / [Name, Title]
Key eligibility (summary)Summarized without changing meaningAge 18–75; ECOG 0–2; CD19+ disease; ≥1 prior line
Prior-treatment requirementWhen reportedRelapsed/refractory after ≥2 lines
Primary outcome/objectiveAs listedSafety (incidence of AE/SAE)
Start / estimated completionDates as listed2026-09 / 2028-04
Registry last update“Last Update Posted” or equivalent2026-08-15
CancerCareE last-checkedDate editorial team opened the registry entry2026-10-24
International access statusConfirmed / Not confirmed / Unavailable per center / UnknownNot confirmed — contact center
Verification noteSource and any discrepancy notedRegistry says Recruiting; no center confirmation obtained
Caveat: A populated record will only be added when every field above has a traceable source. “Not verified” and “Requires confirmation” are valid entries. Do not infer recruitment from “active” or eligibility from diagnosis alone.

Does a Registered CAR-T Trial Mean a Patient Can Receive Treatment?

No. Registration is not a treatment offer. It establishes that a study protocol has been filed with a public registry. It does not establish any of the following:

  • That the study is currently recruiting new participants
  • That a specific patient meets the eligibility criteria
  • That the study center accepts international patients
  • That a treatment slot is available
  • That treatment, tests, travel, or accommodation costs are covered
  • That the investigational product will produce a favorable outcome

Final eligibility is determined by the study team using the full protocol, the patient’s medical history, required screening tests, and other study-specific criteria. Phase, target, and diagnosis alone are insufficient. A Phase 1 study, for example, may be designed primarily to assess safety, not efficacy.

Can International Patients Apply to CAR-T Trials in China?

This must be checked study by study. Public registration on ClinicalTrials.gov or ChiCTR does not imply cross-border access. The following verification stages are distinct and must not be collapsed into a single “accessible” label:

  1. Public registration exists — The trial has a verifiable identifier.
  2. Study center identified — A named hospital or institution is listed.
  3. Contact details found — A reliable public source provides a contact for the study team.
  4. Center contacted — CancerCareE or the patient has initiated contact and received a response.
  5. International eligibility explicitly confirmed — The center has stated that it accepts inquiries or enrollment from the patient’s country of residence.
  6. Recruitment availability confirmed — The center has confirmed that the study is currently enrolling and that a slot may be available.
  7. Required documents and next steps explained — The center has provided a list of documents and a process for formal screening.
If no direct confirmation exists: “International-patient access has not been confirmed. Contact the study center before making travel or financial decisions.” Do not assume that a trial listed as “Recruiting” on a U.S. registry is open to non-Chinese residents.

How to Investigate a Trial: A Step-by-Step Workflow

  1. Identify your diagnosis and the specific trial. Use the registry identifier (NCT or ChiCTR number) to locate the official record.
  2. Open the original registry entry. Do not rely on summaries from hospitals, agencies, or third-party sites.
  3. Check the official recruitment status and the “Last Update” date. A status that has not been updated in 6–12 months requires direct confirmation.
  4. Review the eligibility criteria with your treating oncologist. Pay particular attention to ECOG performance status, prior lines of therapy, organ function, and target-expression requirements.
  5. Confirm the actual study site. A trial may list multiple sites; confirm which site is currently enrolling and whether it is the site you would attend.
  6. Ask whether international patients may apply. This is a separate question from medical eligibility.
  7. Request the protocol-specific screening requirements. Ask what tests, scans, and documents are needed before a formal eligibility decision.
  8. Ask what costs are covered and what are not. See the cost-transparency section below.
  9. Obtain written confirmation before any financial or travel commitment. Verbal statements from a coordinator are not a substitute for written confirmation from the study team.

Your treating oncologist and the study investigators are responsible for medical eligibility decisions. CancerCareE does not make those decisions.

Cost and Financial Transparency

A clinical trial is not necessarily “free.” A sponsor may supply the investigational CAR-T product at no charge, but other expenses can be substantial and are often not covered. Potential cost categories include:

  • Screening tests and procedures required to determine eligibility
  • Routine and additional diagnostic imaging or laboratory tests
  • Hospitalization during infusion and monitoring
  • Management of treatment-related complications (e.g., CRS, ICANS, infections)
  • Supportive care and medications
  • International travel and accommodation for the patient and a companion
  • Translation and local coordination services
  • Follow-up visits and long-term monitoring, which may need to occur in China or be coordinated with your home oncologist

Do not rely on a universal “trial cost” figure. Costs vary by protocol, institution, and the patient’s clinical course. Ask the study center for a written breakdown that specifies what the sponsor covers and what the participant is responsible for.

Questions to ask:

  • Which procedures and medications are covered by the sponsor?
  • Which expenses are paid by the participant?
  • What happens if screening shows I am ineligible — who pays for the screening?
  • Who pays for treatment of adverse events?
  • What follow-up is required, where must it occur, and who covers it?
  • Are international travel and accommodation covered in any circumstance?

Safety and Informed Decision-Making

CAR-T is a specialized cellular therapy. Participation in a clinical trial can involve significant risks. CAR-T therapies may cause serious adverse events including cytokine release syndrome (CRS), neurologic toxicities (ICANS), infections, and prolonged cytopenias. The frequency and severity of these events vary by product, disease, and patient factors.

This is not a prediction of your individual risk. The study’s informed-consent document and the treating clinical team are the appropriate sources for understanding the risks and benefits specific to a given protocol. A registered trial is an investigation, not proof of efficacy for every disease or patient.

How to Contact a Study Center

When contacting a study center, have the following information ready:

  • Trial identifier (NCT or ChiCTR number)
  • Diagnosis and date of diagnosis
  • Relevant pathology and molecular findings, if available
  • Prior treatments and their dates
  • Current clinical status, as described by your treating team
  • Country of residence
  • Preferred language
  • A clear request to confirm current recruitment and international-patient eligibility

Do not post personal medical information in public comments or on social media. If CancerCareE offers an introduction service, it is an information and communication pathway, not a clinical eligibility assessment or a guarantee of enrollment.

Frequently Asked Questions

How many CAR-T clinical trials are registered in China?

A precise, verified total is not published on this page because it requires a documented search methodology and a defined snapshot date. The number changes as trials are registered, completed, or withdrawn. To obtain a current count, search ClinicalTrials.gov and ChiCTR directly using the condition and location filters described in the methodology section. Any number quoted by a hospital or agency should be accompanied by its search date and methodology.

How can I find CAR-T trials that are currently recruiting?

On ClinicalTrials.gov, use the “Recruiting” filter after searching for your condition and location. On ChiCTR, use the recruitment-status filter. Then check the “Last Update” date for each record. A status of “Recruiting” that has not been updated recently may be stale. Always confirm current recruitment directly with the study center before making plans.

Does a recruiting status mean the trial is accepting new patients today?

No. “Recruiting” means the registry record indicates the study is open to enrollment. It does not guarantee that a slot is currently available, that screening capacity exists, or that the study is accepting patients from your country. Direct confirmation from the study center is required.

Can international patients participate in Chinese CAR-T trials?

The answer must be checked study by study. Some centers have experience with international patients; others do not. Public registration on ClinicalTrials.gov or ChiCTR does not indicate whether a trial accepts non-Chinese residents. You must ask the study center directly and obtain confirmation before traveling.

Which cancers are being studied in CAR-T trials in China?

Registered CAR-T trials in China cover a range of hematologic malignancies, including B-cell lymphomas, B-cell acute lymphoblastic leukemia, and multiple myeloma. There is also investigational activity in solid tumors (e.g., gastric, pancreatic, hepatocellular), but these are generally earlier-phase studies. The landscape changes frequently; the registry records are the authoritative source for current studies.

What do Phase I, Phase II, and Phase III mean?

Phase I studies typically focus on safety, dosing, and tolerability in a small number of participants. Phase II studies assess efficacy and further safety in a larger group. Phase III studies compare a new treatment with standard care in a large population and are usually required for regulatory approval. A Phase I trial is not an established treatment; participation is an investigational choice.

Does trial registration mean the treatment is approved?

No. Registration is not approval. A registered trial is an investigation. The investigational product has not necessarily been approved by the NMPA, FDA, EMA, or any other regulatory authority for the indication being studied. Approval status must be checked separately.

Are CAR-T clinical trials free for international patients?

Not necessarily. A sponsor may cover the investigational product, but screening, hospitalization, complications, travel, accommodation, and follow-up may not be covered. Costs vary by protocol and institution. Ask for a written breakdown of what is and is not covered before making any commitment.

Can I determine my eligibility from the registry alone?

No. Registry eligibility criteria are a summary. Final eligibility is determined by the study team after reviewing your full medical history, pathology, imaging, laboratory results, and other protocol-specific requirements. You cannot self-determine eligibility from a public registry entry.

How can I verify a hospital or investigator?

Start with the official registry entry. Check whether the hospital or investigator is named in the record. Cross-check the hospital’s official website and, if available, publications indexed in PubMed that list the investigator and institution. Do not rely solely on information from an agency or coordinator. If the hospital is not named in the registry, ask the study team to confirm the treatment site in writing.

What should I do if a registry entry is outdated?

Contact the study center directly and ask for the current status. If the center does not respond or cannot confirm, treat the trial as not currently available for planning purposes. Do not make travel or financial commitments based on an outdated registry record.

Does CancerCareE provide medical advice or guarantee trial access?

No. CancerCareE is an independent information and access-intelligence platform. We do not provide medical advice, make eligibility determinations, or guarantee enrollment in any trial. We do not charge patients. Any introduction service is a communication pathway, not a clinical service or a promise of access.

Investigate Before You Commit

Use this framework to ask better questions. If you would like help understanding how to verify a trial’s status or prepare documents for a center inquiry, you can request a free information review. We do not charge patient fees.

Continue Exploring

Sources & Methodology References

  1. ClinicalTrials.gov. U.S. National Library of Medicine. Primary public registry for clinical trial records. clinicaltrials.gov
  2. Chinese Clinical Trial Registry (ChiCTR). WHO International Clinical Trials Registry Platform primary registry. chictr.org.cn
  3. CancerCareE. “Clinical Trials for Cancer.” Trial navigation resource. cancercaree.com/cancer-clinical-trials
  4. CancerCareE. “Cancer Treatment Costs: What Patients Should Know.” Total cost of care framework. cancercaree.com/patient-journey/costs
Medical Disclaimer: This page is an educational registry framework and access-intelligence resource. It is not medical advice, a treatment recommendation, or a guarantee of trial enrollment. CancerCareE is not a hospital, clinical-trial sponsor, or medical provider. Final eligibility is determined solely by the study investigators and your treating oncologist. Always verify current status directly with the official registry and study center.